All News
Links:
Dr. John Cush RheumNow ( View Tweet)
Novel Biologic Promising in Mid-Stage Scleroderma Trial
The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported.
Read Article
Filgotinib Approved by the EMA for Rheumatoid Arthritis
On Friday, Gilead and Galapagos announced that the European Commission (EC) has granted marketing authorization for filgotinib (trade name, Jyseleca) their oral, once-daily, JAK1 inhibitor for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have resp
Read Article
RheumNow Podcast – Cardiovascular Risk in Psoriatic Disease (9.25.20)
Dr. Jack Cush reviews the news and Journal articles from the past week on RheumNow.com.
Read Article
EULAR Updated 2019 Recommendations for Psoriatic Arthritis Management
In June 2020, we failed to report on the ARD publication updating the 2019 update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA) - these are presented below.
Read Article
Romilkimab Effective in Early Diffuse Systemic Sclerosis
A phase II study of patients with early diffuse systemic sclerosis (SSc) has demonstrated improvement in SSc skin outcomes by targeting T cells and fibrosis with the bispecific monoclonal antibody romilkimab (RMK).
Read Article
Ustekinumab Early Risk for Cardiovascular Events
JAMA Dermatology reports a claims-based, case-time-controlled French study of 9290 psoriasis patients suggesting that ustekinumab initiation may be associated with an increased risk of acute coronary syndrome or stroke in high risk cardiovascular patients.
Read Article
CXCR3 and Restricted T Cells in Psoriatic Arthritis Inflammation
Research from Oxford University suggests a potential pathogenic role for the chemokine CXCR3 and clonally restricted CD8+ T cells in the pathogenesis of psoriatic arthritis (PsA) based studies of PsA synovial fluid samples obtained by arthrocentesis from 11 patients with large-joint oligo Ps
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast – Lupus Delights (9.18.20)
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com:
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Belimumab Effective in Lupus Nephritis
Dr. Rich Furie has lead a group of investIgators in reporting the significant efficacy of intravenous belimumab when added to standard of care induction therapy in patients with active lupus nephritis. This phase 3, 2-year study included 448 systemic lupus erythematosus patients with biopsy proven lupus nephritis (class III or IV +/- V) patients who required induction therapy and have a UPCR ≥1 g/g.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast - ACR Reproductive Health Slides (9-11-20)
Dr. Jack Cush reviews the 2020 ACR Reproductive Health Guidelines presented all week here on RheumNow.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR 2020 Reproductive Guidelines - Lactation Guidance
In this third excerpt from the ACR guidelines on managing reproductive health issues in rheumatic disease patients, we present recommendations regarding the use of glucocorticoids and guidance on lactation and medication use post-partum.
Read Article